CXCR4 and carcinoma: Blocking TEM recruitment either using CXCR4 antagonist plerixafor or by genetic TEM depletion markedly enhanced the efficacy of CA-4-P treatment in subcutaneous N202 (Neu+) mammary/carcinoma model [50].